Reata Pharmaceuticals’ $281.7 Million Shares Offering

Vinson & Elkins LLP advised Reata Pharmaceuticals, Inc. on the deal.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced its public offering of 2,000,000 shares of its Class A common stock at a price to the public of $140.85 per share, for gross proceeds of $281.7 million.

The offering priced on December 1, 2020 and is expected to close on or about December 4, 2020.

Reata develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation.

The V&E corporate team was led by partner Robert Kimball (Picture) with assistance from senior associate Katherine Frank and associates Grace-Ann Duquette and Joseph Steuert. Advising on tax matters were partner Wendy Salinas and associate Liz Snyder.

Involved fees earner: Grace-Ann Duquette – Vinson & Elkins LLP; Katherine Frank – Vinson & Elkins LLP; Robert Kimball – Vinson & Elkins LLP; Liz Snyder – Vinson & Elkins LLP; Joseph Steuert – Vinson & Elkins LLP; Wendy Trahan Salinas – Vinson & Elkins LLP;

Law Firms: Vinson & Elkins LLP;

Clients: Reata Pharmaceuticals, Inc.;

Print Friendly, PDF & Email

Author: Ambrogio Visconti